HLS Therapeutics Inc has seen a notable uptick in its stock value, closing up 2.19% in the last trading session.
As HLS Therapeutics Inc (HLS.TO) closed at CA$4.20, investors are taking notice of the company's recent performance. The stock's 2.19% rise reflects growing confidence in its revenue growth and future prospects, particularly in its cardiovascular portfolio.
Advertisement
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeAdvertisement
Market cap
$122.60M
52W high
$5.76
52W low
$3.81
1W change
-7.04%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 88.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.21
+88.4% Upside
Current Price
C$3.83
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
28.7%
Annualized
90-Day Vol
24.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.20
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$3.61 | C$3.27 – C$3.98 |
| 60 trading days | C$3.40 | C$2.96 – C$3.91 |
| 90 trading days | C$3.20 | C$2.70 – C$3.80 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should keep an eye on HLS Therapeutics as it continues to build its portfolio and improve its financial outlook, especially with the anticipated launch of new products.
HLS Therapeutics Inc Market Cap Reaches CA$128.54 Million
The market cap of HLS Therapeutics Inc has reached approximately CA$128.54 million, indicating a growing interest in the company as it navigates its financial challenges.
Bull case
HLS Therapeutics is showing promise with a recent increase in revenue and a positive outlook for its upcoming product launches. The company has reaffirmed its financial guidance, which suggests stability and the potential for further stock appreciation.
Bear case
Despite the recent gains, HLS Therapeutics is still operating at a loss, with a profit margin of -18.46%. Investors should be cautious about the company's ability to achieve profitability in the near term.
Recent Financial Performance
Advertisement
HLS Therapeutics recently reported Q1 2026 revenue of CA$12.9 million, marking a 2% increase year-over-year. The growth in Vascepa net sales by 15% has positively influenced investor sentiment. This performance aligns with the company's reaffirmed guidance for 2026, targeting revenue between CA$56–60 million.
Market Reaction and Analyst Outlook
The stock's rise has been supported by analyst coverage, which rates HLS Therapeutics as a 'Buy' with a price target of CA$7.32, indicating a potential upside of 74.29%. This optimism is fueled by the company's ongoing efforts to expand its cardiovascular portfolio and the anticipated approval of new treatments.
Future Growth Potential
Looking ahead, HLS Therapeutics is preparing for the launch of bempedoic acid in Q2 2026, which could further enhance its revenue streams. Investors should watch how the company manages its operational challenges while striving for profitability in the competitive pharmaceutical landscape.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
